News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Accelerating sustainability in Indian pharma industry
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
